Group One Trading
AIMT

Group One Trading’s Aimmune Therapeutics AIMT Stock Holding History

Group One Trading’s Portfolio AIMT Stock Details AIMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-596,200
Closed -$20.5M – 7329
2020
Q3 		$20.5M Buy
596,200
+494,400
+486% +$10.5M 0.06% 263
2020
Q2 		$1.7M Buy
101,800
+3,100
+3% +$52.6K 0.01% 1592
2020
Q1 		$1.42M Buy
98,700
+54,700
+124% +$1.4M 0.01% 1263
2019
Q4 		$1.47M Buy
44,000
+16,800
+62% +$470K 0.01% 1546
2019
Q3 		$570K Buy
27,200
+25,400
+1,411% +$519K ﹤0.01% 2225
2019
Q2 		$37K Buy
1,800
+900
+100% +$18.5K ﹤0.01% 3932
2019
Q1 		$20K Buy
+900
New +$21.2K ﹤0.01% 4042
2018
Q4 		– Sell
-2,000
Closed -$55K – 5703
2018
Q3 		$55K Sell
2,000
-25,300
-93% -$716K ﹤0.01% 3926
2018
Q2 		$734K Buy
27,300
+20,000
+274% +$612K 0.01% 1990
2018
Q1 		$232K Sell
7,300
-15,600
-68% -$549K ﹤0.01% 2677
2017
Q4 		$866K Buy
+22,900
New +$739K 0.01% 1833

Group One Trading's AIMT Position: Q2 2020 in Review

Group One Trading sold out of Aimmune Therapeutics (AIMT) in Q2 2020, closing a stake of 10,617 shares — an estimated $180K sold.

Group One Trading first reported a position in AIMT in Q3 2017 and held it in 6 quarters. The position peaked at $561K in Q1 2018. 165 funds tracked by Wall St. Rank hold AIMT as of Q2 2020.

  • Group One Trading reported no remaining Aimmune Therapeutics position as of Q2 2020 after selling out during the quarter.
  • Group One Trading sold 10,617 Aimmune Therapeutics shares in Q2 2020, an estimated $180K.
  • Group One Trading first reported a position in Aimmune Therapeutics in Q3 2017 and held it in 6 quarters.
  • Group One Trading's Aimmune Therapeutics position peaked at $561K in Q1 2018.
  • 165 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q2 2020.

Based on Group One Trading's 13F filing for Q2 2020, filed 13 Aug 2020.